Selexis & Teneobio have signed CLAs for the development of Teneobio’s UniAbs™, a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer
Selexis to Develop High-performance Research Cell Banks to Expedite the Manufacturing of Immunotherapy Clinical Candidates Designed to Target Cancers of High Unmet Need
MuBase offers a user-friendly experience while searching a large collection of model data, including tumor pathology, genomic characterization, and in vivo pharmacology data with standard of care a...
CrownBio’s models are unparalleled in their translatability and enable clinically translatable evaluation of therapeutics that target not only kidney complications, but also hyperglycemia in diabet...
2 of 3
Receive JSR Life Sciences news on your RSS reader.